PDCD1 and neoplasm: Antibodies against PD‐1 or PD‐L1 prevent interaction between PD‐1 and its ligand, block the activation of PD‐1, and thereby restore the activity of CTL to lyse PD‐L1 expressing target cells and shrink tumor in vivo (Hirano et al, 2005).